Latest News
-

Friday - November 13, 2020
Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
Pediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatric thromboembolism program completed to date, including the phase III EINSTEIN-Jr. study » more 
-
Thursday - November 12, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases / Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient access to cell and gene therapies » more
-

Monday - November 9, 2020
Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes
Regulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicine » more 
-
Tuesday - November 3, 2020
Bayer:
Challenging third quarter – Group outlook confirmed
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering – higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash flow falls by 2.1 percent to 1.237 billion euros » more
-
Wednesday - October 28, 2020
Bayer launches first Global Creative Council: raising the bar for the Consumer Health Industry
Senior Marketing Leaders from top creative agencies and world-renowned brands volunteering to work with Bayer to enhance creativity and inspire consumers to take better care of their health » more
-
Tuesday - October 27, 2020
The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer’s low-volatility dicamba product
The new registration follows launch announcement for XtendFlex® soybeans and enables full potential of industry-leading Roundup Ready® Xtend Crop System » more
-
Tuesday - October 27, 2020
Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development » more
-
Tuesday - October 27, 2020
60% of parents & parents-to-be do not realise that nutrition directly impacts a baby's growth and development during pregnancy
Bayer launches Mission 1000+ campaign to empower parents with knowledge about the role of nutrition in their baby’s development » more
-
Monday - October 26, 2020
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical candidates for hemophilia and Duchenne muscular dystrophy / Acquisition secures additionally revenue generating Contract Development and Manufacturing Business based on highly efficient Pro10™ Cell line / AskBio to operate autonomously and on an arms-length basis / Purchase price of USD 2 billion upfront and up to USD 2 billion in success-based milestone payments » more
-

Monday - October 26, 2020
Not intended for U.S. and UK Media
Rivaroxaban application submitted to U.S. FDA for new indication in patients after lower-extremity revascularization due to symptomatic PAD
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD » more 
-

Friday - October 23, 2020
Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients
The companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions (NTRK1, NTRK2 and NTRK3), to inform treatment decisions(1) / Vitrakvi™ (larotrectinib) is the first and only TRK-specific inhibitor approved in the U.S. for adult and pediatric patients with TRK fusion cancer across all solid tumors and is under review in other markets around the world » more 
-

Friday - October 23, 2020
Not intended for U.S. and UK Media – Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)’s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine » more 
-
Thursday - October 15, 2020
Leaps by Bayer leads USD 17 million Series B financing in biotech company Azitra
Harnessing the human skin microbiome to develop cutting-edge solutions moving the paradigm from treatment to cure in dermatology / Investment to support advancement of Azitra’s technology platform for both clinical and consumer programs » more
-

Wednesday - October 14, 2020
Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma
Phase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adult patients with relapsed follicular lymphoma (FL) based on the Phase II CHRONOS-1 study » more 
-
Tuesday - October 13, 2020
Bayer Future of Farming Dialogue focuses on importance of sustainability in agriculture
Bayer helping transform the food system through innovation in agriculture
Despite the challenges posed by Covid-19, Bayer confirms significant progress on its sustainability commitments / Highly innovative carbon initiatives are redefining the value of farming by rewarding farmers for generating carbon credits when adopting climate-smart practices / Game-changing launch of VITALA, the first global launch of a short stature maize hybrid in Mexico, to help farmers produce more while using less resources » more
-

Monday - October 12, 2020
Not intended for U.S. and UK Media - American Society of Nephrology (ASN)’s Kidney Week 2020 Reimagined:
Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020
FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of poster presentations in cardiovascular and kidney diseases will be presented » more 
-
Wednesday - September 30, 2020
Bayer to accelerate transformation to address challenging market environment and enable additional growth investments
Adjusted outlook for 2020 confirmed / 2021 sales expected at approximately 2020 levels despite significant headwinds from COVID-19 pandemic; 2021 core earnings per share expected to be slightly below 2020 levels at constant exchange rates / Lower than expected outlook in the agricultural market likely to lead to mid-to-high single-digit billion-euro non-cash impairment charges in the Crop Science business / Strengthening margin profile and funding of additional investments in innovation and growth through additional operational savings, targeted at more than 1.5 billion euros annually as of 2024 / Dividend policy to remain unchanged, payout ratio planned at lower end of 30-to-40 percent range of core earnings per share in the coming years » more
-
Monday - September 21, 2020
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Ag » more
-

Thursday - September 17, 2020
ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors
78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7) » more 
-
Tuesday - September 15, 2020
Bayer Launches Large-scale Pre-launch Trial of New Tomato Varieties with Resistance to Tomato Brown Rugose Fruit Virus (ToBRFV)
The trials, which begin late September in Mexico, will target two varieties of Roma tomatoes which show little or no symptoms of ToBRFV / Developing these varieties aligns with Bayer’s commitment to provide fruit and vegetable seeds from its Seminis and De Ruiter brands which help growers combat the challenges they face each season » more
Copyright @ Bayer AG